Bradykinin B2 Receptor Antagonists

DBCAT001770Therapeutic category

Compounds and drugs that inhibit ligand binding or cellular signaling by BRADYKININ B2 RECEPTORS. A DrugBank category of 2 drugs. 1 of them is approved.

Also known as: Antagonists, Bradykinin B2 · B2 Antagonists, Bradykinin · Bradykinin B2 Antagonists · Bradykinin B2 Receptor Blockers · Bradykinin B2 Receptor Inhibitors
Drugs: Fasitibant
Icatibant

What you can answer from here — as of May 31, 2018

2DrugsEach linked to its full drug card

Listed above

2Drug targetsEvery drug–target pair in the class, with bond type

65Marketed productsAcross the regions we cover, with dosage forms and routes

2Routes of administrationHow the drugs in this class are given

Which targets do Bradykinin B2 Receptor Antagonists share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account